FORM CIBB-02[See Rule 3(2)]

Manufacturing feasibility assessment

Serial No. 2026-07-23-0021Issued: 23 Jul 2026
1.Product
soft exoskeleton
2.Submitted by
Anonymous
3.Target market
Global
4.Target retail
$3,000-10,000

5. Verdict

Limit it to clinician-fitted, low-torque gait assistance with fail-safe release and one indication; pursue ISO 13485/14971 and regional clearance, starting with a 50-user pilot.

6. Subsystems

  1. 6.1 Textile load-path harnessMEDIUM
  2. 6.2 Actuation and transmissionMEDIUM
  3. 6.3 Controls and functional safetyMEDIUM
  4. 6.4 Power systemMEDIUM
  5. 6.5 User interface and caregiver setupMEDIUM
  6. 6.6 Sizing, hygiene, and serviceMEDIUM

7. Bill of materials

Item1001,00010,000
7.1 Waist-mounted actuator modules and gearboxes$700–1,000$420–650$270–420
7.2 Battery pack, BMS, charger, and power harness$260–380$170–260$115–180
7.3 Sensors, control PCB, safety electronics, and firmware loading$250–390$150–245$95–160
7.4 Bowden cables, anchors, quick-release hardware, and covers$170–280$105–175$70–115
7.5 Technical textile harness, pads, closures, and washable liners$230–360$145–235$90–150
7.6 Assembly, calibration, end-of-line test, and packaging$260–420$155–260$100–170
7.7 Estimated landed manufacturing BOM$1,870–2,830$1,145–1,825$740–1,195
7.8 TOOLING (one-time)$450,000–1,100,000 for textile cutting fixtures, test rigs, cable assembly fixtures, production calibration stations, and low-volume molds.

At 10,000 units, tooling adds about $45–110 per unit, or roughly 0.5–3.7% of the $3,000–10,000 retail range. The 10k BOM remains below 40% of the $3,000 entry retail, but only near the upper end of the BOM range.

8. Gates to clear

  1. 8.1 [DFM]

    A universal soft exoskeleton for frail users produces inconsistent fit, cable routing, pressure points, and assistance geometry.

    Path: Restrict Gen 1 to a single body region and assistance task, use 3–5 validated size bands, then run wear trials with a medical-textile OEM and contract manufacturer.

  2. 8.2 [Certification]

    Global therapeutic, fall-prevention, or rehabilitation claims substantially increase evidence, safety, and regulatory scope.

    Path: Launch by region: EU CE marking under MDR with ISO 13485, ISO 14971, IEC 62366-1 and IEC 60601-1/-1-2 assessment; pursue US FDA pathway separately after predicate and intended-use review.

  3. 8.3 [Tooling]

    The $3,000 retail floor cannot support low-volume production, broad global certification, and clinician service if BOM stays near the 100-unit estimate.

    Path: Begin with clinic or distributor deployment at $6,000–10,000 retail, use contract manufacturing at 500–1,000 units, and fund dedicated tooling only after demand supports 10,000-unit annual volume.

9. Prototype sequence

  1. 9.1Freeze a single indication, body region, user weight range, and clinic-supervised use model.This converts an overly broad global device concept into testable safety, fit, and regulatory requirements.
  2. 9.2Build 15–30 adjustable alpha units using off-the-shelf motors, batteries, sensors, and sewn textile harnesses.Early units should expose comfort, donning, cable-routing, and caregiver workflow failures before custom tooling.
  3. 9.3Run supervised fit, mobility, pressure, and fault-response studies with geriatric users and clinicians.Evidence is needed to set assistance limits, size bands, quick-release requirements, and realistic intended-use claims.
  4. 9.4Complete design verification with production-intent electronics, battery protection, washable liners, and end-of-line calibration.This establishes the design-history and risk-management evidence needed before formal regulatory testing.
  5. 9.5Pilot 100–300 units through an ISO 13485-capable medical-device contract manufacturer and regional regulatory sequence.The pilot validates yield, service burden, landed cost, and certification readiness before committing production tooling.

Assessment criteria: J. Tanikella · Engine: GPT-5.6 Terra.

This is a system generated assessment issued on the basis of the information furnished above. It is produced by an automated model and may be incomplete, inaccurate, or fabricated. It is not a substitute for a DFM review by a manufacturer, nor for independent engineering, legal, or manufacturing due diligence.